Loading…
Oramed Pharmaceuticals Inc. is projected to rise to $4.77 by 2027, a +17% move from its current price of $4.07. ORMP is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $3.97 | $4.07 | $4.18 | +0.03% |
| Aug 5 | $3.93 | $4.07 | $4.22 | +0.06% |
| Aug 6 | $3.90 | $4.07 | $4.26 | +0.09% |
| Aug 7 | $3.87 | $4.07 | $4.29 | +0.12% |
| Aug 8 | $3.85 | $4.08 | $4.32 | +0.14% |
| Aug 9 | $3.83 | $4.08 | $4.34 | +0.17% |
| Aug 10 | $3.81 | $4.08 | $4.36 | +0.20% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.81 | $4.08 | $4.36 | +0.20% |
| Week 2 | $3.71 | $4.09 | $4.50 | +0.40% |
| Week 3 | $3.64 | $4.09 | $4.60 | +0.61% |
| Week 4 | $3.58 | $4.10 | $4.70 | +0.81% |
| Week 5 | $3.53 | $4.11 | $4.78 | +1.01% |
| Week 6 | $3.49 | $4.12 | $4.86 | +1.22% |
| Week 7 | $3.45 | $4.13 | $4.94 | +1.42% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Oramed Pharmaceuticals Inc. is a healthcare company focused on the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes.
The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Oramed Pharmaceuticals Inc., ticker ORMP, operates in the Healthcare sector and is a small-cap with a current price of $3.97, a market capitalization of $162.48M, and a rank of 3928.
The year-by-year forecast presents a path of gradual upside from 2026 through 2050, starting with a 2026 average price at $3.97 and culminating in a 2050 average of $36.96. The implied ROI rises from 0% in 2026 to 830.9% by 2050, indicating substantial long-run upside on the given trajectory.
From 2027 to 2030 the averages progress to $4.59, $5.88, $6.93 and $7.96 respectively, with corresponding ROIs of 15.6%, 48%, 74.7% and 100.4% as the forecast horizon extends. The later years extend the upward trend further, with 2031–2035 averages of $8.56, $8.42, $9.45, $10.93 and $12.74 and ROIs of 115.7%, 112.1%, 138.1%, 175.3% and 221% respectively, and the 2040/2050 averages of $16.93 and $36.96 with ROIs of 326.4% and 830.9%.
A major floor 21.5% below — a decisive break under it would weaken the trend.
The nearest floor, 4.7% below — buyers have tended to step in here.
The nearest ceiling, 22.9% above — a clean break opens room to run.
A major ceiling 33.6% above — clearing it would confirm fresh momentum.
Key ORMP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ORMP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.10 | Sell | $4.08 | Sell |
| MA 10 | $4.08 | Sell | $4.09 | Sell |
| MA 20 | $4.12 | Sell | $4.12 | Sell |
| MA 50 | $4.09 | Sell | $4.09 | Sell |
| MA 100 | $3.93 | Buy | $3.91 | Buy |
| MA 200 | $3.44 | Buy | $3.55 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.03 | Neutral |
| Stoch RSI (14) | 55.90 | Neutral |
| CCI (20) | -29.13 | Neutral |
| Williams %R (14) | -50.00 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | 0.25 | Buy |
| Bollinger %B (20,2) | 0.42 | Neutral |
| Stochastic %K (14) | 50.00 | Neutral |
| TRIX (15) | -0.06 | Sell |
| Awesome (5,34) | -0.09 | Sell |
| Ultimate (7,14,28) | 53.33 | Neutral |
| Momentum (10) | 0.04 | Buy |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 4.07 | Sell |
| ADX (14) | 9.74 | Neutral |
| ATR (14) | 0.10 | Info |
The near-term technical picture is labeled BULLISH in the data.
Key momentum and price indicators show a current RS I14 of 40, with the 50-day simple moving average at $4.09 and the 200-day simple moving average at $3.42. Near-term support stands at $3.77 and resistance at $5.00, forming a baseline for the next trading moves.
The 30-day price range is $3.35 to $4.71, reflecting a modest drift with a wide intraday variation. Annualized volatility is reported at 50%, underscoring elevated price swings in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.91 | $4.07 | $5.47 | 0% | Neutral | |
| $3.83 | $4.77 | $6.28 | +17% | Neutral | |
| $4.80 | $6.14 | $8.37 | +51% | Bullish | |
| $5.59 | $7.31 | $10.25 | +80% | Bullish | |
| $6.30 | $8.40 | $12.05 | +107% | Bullish | |
| $6.70 | $9.09 | $13.30 | +123% | Bullish | |
| $6.57 | $9.05 | $13.49 | +122% | Bullish | |
| $7.25 | $10.14 | $15.36 | +149% | Bullish | |
| $8.31 | $11.80 | $18.15 | +190% | Bullish | |
| $9.66 | $13.91 | $21.69 | +242% | Bullish | |
| $12.17 | $18.63 | $30.84 | +358% | Bullish | |
| $24.23 | $41.20 | $74.34 | +912% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.91 | $4.07 | $4.92 | +0.00% |
| September 2026 | $3.45 | $4.07 | $4.93 | -0.08% |
| October 2026 | $3.52 | $4.18 | $5.12 | +2.74% |
| November 2026 | $3.67 | $4.38 | $5.41 | +4.83% |
| December 2026 | $3.66 | $4.40 | $5.47 | +0.38% |
Click any year to see its month-by-month ORMP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ORMP to range from $2.91 to $5.47 through 2026. The $4.07 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The ORMP price prediction for 2027 points to an average of $4.77 (low $3.83, high $6.28) — a potential gain of +17% on today's $4.07. Price action looks broadly range-bound.
In 2028, ORMP is projected to trade between $4.80 and $8.37, averaging $6.14 — a potential gain of +51% from today's $4.07. That is up +29% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Oramed Pharmaceuticals Inc.'s 2029 outlook centres on $7.31, within a $5.59 to $10.25 range. That is up +19% on the projected 2028 average. That marks a +80% change versus current levels. Momentum favours further upside here.
By 2030, ORMP could reach as high as $12.05, with a base case around $8.40 and support toward $6.30 — roughly +107% from $4.07. Buyers look set to stay in control over this stretch.
Expect ORMP to range from $6.70 to $13.30 through 2031. The $9.09 average target implies a +123% move from current prices. That is up +8% on the projected 2030 average. Momentum favours further upside here.
The ORMP price prediction for 2032 points to an average of $9.05 (low $6.57, high $13.49) — a potential gain of +122% on today's $4.07. Buyers look set to stay in control over this stretch.
In 2033, ORMP is projected to trade between $7.25 and $15.36, averaging $10.14 — a potential gain of +149% from today's $4.07. That is up +12% on the projected 2032 average. Momentum favours further upside here.
Oramed Pharmaceuticals Inc.'s 2034 outlook centres on $11.80, within a $8.31 to $18.15 range. That is up +16% on the projected 2033 average. That marks a +190% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, ORMP could reach as high as $21.69, with a base case around $13.91 and support toward $9.66 — roughly +242% from $4.07. Momentum favours further upside here.
Expect ORMP to range from $12.17 to $30.84 through 2040. The $18.63 average target implies a +358% move from current prices. That is up +34% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The ORMP price prediction for 2050 points to an average of $41.20 (low $24.23, high $74.34) — a potential gain of +912% on today's $4.07. Momentum favours further upside here.
Investing $1,000 in ORMP today (≈ 245.700246 ORMP) could be worth
$10,122.22
+$9,122.22 (+912%) by 2050 · US Dollar
Based on the average projected ORMP price of $41.2 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ORMPwould be worth at today's price.
$1,000 invested in ORMP on Jul 31, 2025 (≈ 465.116258 ORMP) would be worth
$1,893.02
+$893.02 (+89.3%) today · 1.89× · US Dollar
Based on a ORMP entry price of $2.15 vs. today's $4.07.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.03 | $1,009.93 | +1.0% |
| 1 month ago | $4.61 | $882.86 | -11.7% |
| 3 months ago | $3.98 | $1,022.61 | +2.3% |
| 6 months ago | $3.4 | $1,197.06 | +19.7% |
| 1 year ago | $2.15 | $1,893.02 | +89.3% |
| All time (5.0y) ago | $15.1 | $269.54 | -73.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ORMP forecast.
Our base-case forecast reaches $8.10 around 2030.
Implied market cap at $8.10: $331.5M
The multi-year forecast depicts a clear upward trajectory, with the 2030 average price at $7.96 and a 100.4% ROI, the 2040 average at $16.93 with a 326.4% ROI, and the 2050 average at $36.96 delivering an 830.9% ROI, all under a bullish sentiment across those years.
This path implies meaningful upside from the current price level of $3.97, supported by sustained improvements in annual averages through the forecast horizon. The outlook benefits from ongoing developments around ORMD-0801, the oral insulin capsule in Phase III trials for diabetes, and the license arrangement with Oravax for oral COVID-19 vaccines, though actual results depend on future clinical and regulatory outcomes.
Risks include trial outcomes, regulatory approvals, and broader market dynamics; as with all forecasts, these are estimates and not guarantees. The forecast imagery suggests a strong long-term upside despite near-term uncertainties.
Tap a question to reveal the answer.
Avg $7.96, Min $5.95, Max $11.45, ROI 100.4, sentiment BULLISH.
Forecasts show rising averages and bullish sentiment from 2028 onward, with ROI reaching 830.9% by 2050; these are estimates, not guarantees.
The 2035 max is $19.96; the 2040 max is $28.14.
Current price $3.97; Market cap $162.48M.
RSI14 40; SMA50 $4.09; SMA200 $3.42; Support $3.77; Resistance $5.00; 30-day range $3.35-$4.71; Sentiment BULLISH.
Oramed Pharmaceuticals Inc. Community Discussion
0Share your Oramed Pharmaceuticals Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.